Retatrutide for Obesity

(TRIUMPH-9 Trial)

This trial tests the safety and effectiveness of a new treatment called retatrutide for individuals who are overweight or have obesity but do not have type 2 diabetes. It examines various methods to gradually increase the dose of retatrutide to determine the most effective approach. Ideal candidates for this trial have a BMI of 30 or higher, or a BMI of 27 or higher with conditions like high blood pressure or sleep apnea, and have struggled to lose weight through dieting. As a Phase 3 trial, this study represents the final step before FDA approval, providing participants an opportunity to contribute to a potentially groundbreaking treatment.

The trial does not specify if you need to stop taking your current medications, but you cannot have taken weight loss drugs in the 90 days before screening.

Research has shown that retatrutide is generally safe and well-tolerated. Studies have found that adults with obesity lost a significant amount of weight and experienced improved metabolism while using retatrutide. Importantly, the treatment proved safe for participants.

Retatrutide is unique because it targets multiple pathways involved in weight regulation, which sets it apart from many current obesity treatments that typically focus on a single hormone or receptor. Unlike existing medications like liraglutide or semaglutide, which primarily act on the GLP-1 receptor, retatrutide is a triple agonist, meaning it also engages the GIP and glucagon receptors. This multi-target approach may enhance weight loss and improve metabolic health more effectively. Researchers are excited about retatrutide because it could offer a more comprehensive solution to obesity, potentially leading to better outcomes for patients.

Research has shown that retatrutide holds promise for weight loss in individuals with obesity. One study revealed that participants lost between 22.8% and 24.2% of their weight after 48 weeks of treatment with doses ranging from 8 mg to 12 mg. Another study found that retatrutide led to an average weight loss of up to 24.2%, equating to about 26.2 kg for someone starting at a higher weight, after 48 weeks. Retatrutide affects three hormone receptors, slowing stomach emptying and reducing food intake, which aids in weight loss. Overall, these findings suggest retatrutide could be a highly effective treatment for obesity.¹³⁶⁷⁸